Cancer Immunology In Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has undergone remarkable therapeutic transformation with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, accumulating evidence indicates that durable disease control depends not only on kinase inhibition, but also on effective anti-leukemic immunity. At diagnosis, both innate and adaptive immunity are profoundly dysregulated, characterized by an impaired natural killer cell function, T-cell exhaustion, the expansion of immunosuppressive cell populations, and the activation of immune checkpoint pathways. TKIs differentially remodel the immune microenvironment through off-target immunomodulatory effects, potentially contributing to treatment-free remission (TFR) in selected patients. Recent studies have further identified leukemic stem cell immune evasion mechanisms, bone marrow niche interactions, and host immunogenetic factors as factors associated with long-term disease control. This review summarizes current advances in cancer immunology in CML and discusses emerging immunological biomarkers and therapeutic strategies to achieve durable immune surveillance, TFR, and a functional cure.
Authors
- Hiroshi Ureshino (ORCID: https://orcid.org/0000-0002-5034-3699)
Institutions
- Saga University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2169/internalmedicine.8443-26
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00